BioPharmSignal logoBioPharmSignal

Biotech News

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Adial Pharmaceuticals (ADIL)Adial PharmaceuticalsEarnings

Received Favorable Feedback from US and EU Regulatory Agencies

Advancing Discussions with Potential Strategic Partners

Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023

GLEN ALLEN, Va., April 02, 2024 (GLOBE...

Related news

ADILAdial Pharmaceuticals2025-03-04 08:30 EST

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

ADILAdial Pharmaceuticals2025-05-15 08:30 EST

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

View all latest news

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.

Recent company news

ADILAdial Pharmaceuticals2025-06-11 08:00 EST

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

ADILAdial Pharmaceuticals2025-05-15 08:30 EST

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ADILAdial Pharmaceuticals2025-05-13 08:30 EST

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

ADILAdial Pharmaceuticals2025-05-08 08:30 EST

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

ADILAdial Pharmaceuticals2025-05-02 11:48 EST

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Stock data

Close
6.22 USD
Market cap
5.06M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States